GLOW peptide.

GLOW = GHK-Cu + BPC-157 + TB-500

GLOW peptide combines three ingredients: the copper peptide GHK-Cu, BPC-157 and TB-500. GHK-Cu adds the skin and collagen focus to the two recovery peptides in the Wolverine Stack. GLOW is a blend name, not a fourth peptide.

The supplied vial contains 50 mg GHK-Cu + 10 mg BPC-157 + 10 mg TB-500. That is 70 mg total at a 5:1:1 ratio by weight. Its TB-500 is the full-length, 43-amino-acid thymosin beta-4 molecule. [1]

The blue colour comes from GHK-Cu. Its 50 mg label refers to the copper–peptide complex, not 50 mg of elemental copper. The vial and pen use the same ingredient ratio, but contain different totals and require different preparation. [2]

GLOW peptide benefits

For wrinkles, scars, loose skin and hair, the formulation matters. A cream, a wound gel and an injected blend expose different tissues to different amounts. There is no published controlled human trial establishing that this GLOW combination reproduces the topical results.

Skin, hair, joint and tendon benefits →

GLOW dosage and ingredient amounts

A 3.5 mg total portion contains 2.5 mg GHK-Cu, 500 mcg BPC-157 and 500 mcg TB-500. A documented GLOW account used that amount on five days per week. The same account described marked afternoon fatigue, so the number should be read with that outcome attached. [7]

These are documented schedules, not a validated dose for everyone. 3 mg per administration and 3 mg per day are different totals. Likewise, “500 mcg” could mean 500 mcg of the whole blend or 500 mcg of BPC-157 within it.

For the 70 mg vial at a final 2 mL volume, the concentration is 35 mg/mL. A 3.5 mg target equals 0.1 mL, or 10 units on a U-100 syringe. At a final 3 mL volume, the same target equals 0.15 mL, or 15 units. These are arithmetic examples; the final volume must match the actual preparation.

Open the GLOW calculator → It shows the liquid volume and all three ingredient amounts together.

GLOW cycle length

One published clinic schedule uses 8–12 weeks. The five-days-on, two-days-off pattern above describes days within a week; it does not establish the total course length. A weekend break is also different from several weeks off between courses. [8] [7]

Cycle schedules, timing and course quantities →

GLOW vial and prefilled pen

Research-labelled products. Drawings show the formats; they are not product photographs.

The pen contains about 2.14 times the vial's total blend amount: nominally 150 mg versus 70 mg. It is already dissolved at 50 mg/mL in a 3 mL cartridge. The vial's concentration depends on the final volume used to dissolve its powder. [2]

The pen specifications list rounded component amounts of 107 mg GHK-Cu, 21.4 mg BPC-157 and 21.4 mg TB-500. Their 149.8 mg sum reflects rounding around the nominal 150 mg label. A known concentration still does not supply a pen click size; the device calibration is needed for that conversion.

Compare GLOW products, storage and the redacted COA →

GLOW results and timelines

Hair changes also take time to measure. A small topical GHK-Cu eyebrow study found a hair-count difference at 12 weeks, with no significant count difference at weeks four or eight. That result does not establish a scalp-hair or injectable GLOW response. [10]

GLOW before and after: changes, nonresponse and time after stopping →

GLOW, Wolverine Stack and KLOW

Combining GLOW with Wolverine Stack duplicates BPC-157 and TB-500. Adding a GHK-Cu product duplicates the copper peptide. For example, 3.5 mg of this GLOW blend plus 1 mg of a 1:1 Wolverine blend totals 2.5 mg GHK-Cu + 1 mg BPC-157 + 1 mg TB-500. That is ingredient arithmetic, not an extra-stack recommendation.

Different GLOW products can also have different ratios. Copying a schedule by the word “GLOW” alone can change all three ingredient amounts. Match the actual composition before comparing quantities. [2]

GLOW side effects

GLOW safety details →

Redacted GLOW COA

REDACTED COPY · IN-HOUSE REPORT

GLOW blend — powder lot PL-2609-043

99.72% combined HPLC area purity

Label total50 + 10 + 10 mgLC-MS identity3 of 3 componentsEndotoxin0.05 EU/mgSterility testNo growth after 14 daysAnalysis date17 September 2026Sampled units2 of 250

Two sampled units of the named powder lot. HPLC area purity is not a fill-content assay. Shown with both formats; no finished-pen test or batch linkage is supplied.

Open redacted COA

99.72% is combined HPLC area purity. The certificate identifies all three ingredients in two sampled powder vials from lot PL-2609-043. It does not independently measure each vial's milligram fill or test the finished 3 mL pen. The redacted two-page report is available beside both formats. [1]